Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following drugs should be given in a sustained-release oral dosage form?

An antihypertensive with a plasma half-life of 3 hours. *An anti-arrhythmic drug with a plasma half life of 10 seconds used for acute treatment of PSVT* - An extremely short **half-life** (10 seconds) indicates a drug suitable for **rapid-onset, acute interventions**, where the effect is needed immediately and for a very brief duration, making sustained release impractical. - Drugs like **adenosine**, used for acute PSVT, are given intravenously as a rapid bolus due to their ultra-short half-life, not in an oral sustained-release form. *Anti inflammatory drugs with the plasma half life of 24 hours* - A long **half-life** (24 hours) typically means the drug can be administered **once daily** to maintain therapeutic concentrations, rendering a sustained-release formulation unnecessary. - Such drugs already provide **prolonged action** and do not benefit significantly from further extension of release. *Hypnotic drugs with a plasma half life of 2 hours* - While a 2-hour half-life for a hypnotic might suggest potential for sustained release to prolong sleep, the goal of hypnotics is often a **rapid onset and relatively short duration** to avoid hangover effects. - Sustained release might cause **daytime sedation** and interfere with normal wakefulness, which is generally undesirable for this class of drugs. ***An antihypertensive with a plasma half-life of 3 hours*** - A short **half-life** (e.g., 3 hours) often necessitates frequent dosing to maintain therapeutic levels, making a **sustained-release formulation desirable** for patient compliance and consistent drug exposure. - Sustained-release dosage forms are particularly useful for drugs requiring **long-term, stable plasma concentrations**, such as antihypertensives, to manage chronic conditions effectively.

Q: Which of the following statements is true regarding competitive reversible antagonism?

Efficacy and Vmax remain unchanged.. ***Efficacy and Vmax remain unchanged.*** - In competitive reversible antagonism, the antagonist binds to the same receptor site as the agonist but can be overcome by increasing the agonist concentration [2]. This means the **maximum effect (efficacy or Vmax)** of the agonist can still be achieved, although a higher dose is needed [2]. - The antagonist does not alter the intrinsic ability of the agonist to produce a full response, only its **apparent affinity** for the receptor. - This is the hallmark of competitive reversible antagonism: **rightward shift of the dose-response curve with no change in maximum response** [2]. *Potency remains unchanged in the presence of a competitive antagonist.* - **Potency** is a measure of the amount of drug needed to produce a given effect (often defined by EC50 or ED50) [3]. - A competitive antagonist requires a **higher concentration of agonist** to achieve the same effect, thus **decreasing the apparent potency** of the agonist [4]. - The dose-response curve shifts to the right (parallel shift) [4]. *ED50 remains unchanged in competitive reversible antagonism.* - **ED50 (effective dose 50)** is the dose that produces 50% of the maximum effect. - Because competitive antagonists shift the dose-response curve to the right, a **higher ED50** is required to achieve 50% of the maximum effect in the presence of an antagonist [4]. *Affinity (Kd) remains unchanged in competitive reversible antagonism.* - The **dissociation constant (Kd)** represents the affinity of a drug for its receptor [1]. - In competitive reversible antagonism, the antagonist increases the **apparent Kd** of the agonist (reduces apparent affinity), requiring more agonist to achieve receptor occupancy. - The **intrinsic Kd** of the agonist doesn't change, but its apparent affinity is reduced due to competition with the antagonist.

Q: A partial agonist has:

High affinity with low intrinsic activity. ***High affinity with low intrinsic activity*** - A **partial agonist** binds to the receptor with **high affinity** [1] but elicits a submaximal response, indicating partial activation [1],[2]. - Its **intrinsic activity** is greater than zero but less than that of a full agonist [2]. *High affinity with no intrinsic activity* - This describes an **antagonist**, which binds to the receptor with **high affinity** but produces no biological effect (zero intrinsic activity). - An antagonist simply blocks the action of other agonists. *Low affinity with high intrinsic activity* - While binding affinity and intrinsic activity are distinct properties, a drug with **high intrinsic activity** typically produces a strong effect, and low affinity would mean a higher concentration is needed for that effect. This combination does not define a partial agonist. - A full agonist would have **high intrinsic activity**, but affinity can vary. *Low affinity with low intrinsic activity* - A drug with both **low affinity** and **low intrinsic activity** would be a very weak partial agonist, requiring high concentrations to produce only a small effect. - While it technically describes a type of partial agonist, the defining characteristic of a partial agonist is often highlighted by its ability to bind effectively (high affinity) but only partially activate (low intrinsic activity) a receptor.

Q: Which of the following is a metabotropic receptor?

Beta receptor for norepinephrine. ***Beta receptor for norepinephrine*** - **Beta-adrenergic receptors** (like those for norepinephrine) are **G protein-coupled receptors**, which are the hallmark of metabotropic receptors. - Activation of these receptors leads to a cascade of **intracellular signaling events** through second messengers, rather than direct ion channel opening. *GABA-A receptor* - The **GABA-A receptor** is a **ligand-gated ion channel** (ionotropic receptor) that, when activated by GABA, allows chloride ions to flow into the neuron. - This influx of **chloride ions** causes hyperpolarization, leading to an inhibitory effect. *Nicotinic acetylcholine receptor* - The **nicotinic acetylcholine receptor** is a **ligand-gated ion channel** (ionotropic receptor) that, upon binding acetylcholine, directly opens to allow the passage of sodium and potassium ions. - This ion movement causes **depolarization** and excitation of the postsynaptic cell. *NMDA receptor* - The **NMDA receptor** is a type of **glutamate receptor** that functions as a **ligand-gated ion channel** (ionotropic receptor) and is permeable to Na+, K+, and Ca2+. - Its activation requires both **glutamate binding** and depolarization to remove a magnesium block, directly leading to ion flow.

Q: Renal threshold of a drug means:

Drug concentration above which it appears in urine. ***Drug concentration above which it appears in urine*** - The **renal threshold** refers to the plasma concentration of a substance that, when exceeded, leads to its excretion in the urine because the renal tubules' reabsorptive capacity is saturated. - For drugs, if their concentration in the blood surpasses this threshold, the kidneys are unable to reabsorb all of it, resulting in its appearance in the urine. *Drug concentration below which it appears in urine* - This statement is incorrect as it contradicts the definition of renal threshold, which implies excretion when concentrations are *high*, not low. - Substances generally do not appear in urine when their concentration is below the renal threshold because the kidneys efficiently reabsorb them. *Drug concentration above which it appears in blood* - This option is flawed because drugs are always present in the blood if administered; their appearance in the blood is not dictated by a threshold in this context. - The renal threshold specifically relates to the kidney's handling of substances and their subsequent excretion into the urine. *Drug concentration at which it starts to be metabolized* - **Metabolism** primarily occurs in the liver, not at a specific renal concentration threshold. - The phrase "renal threshold" is explicitly about kidney function and urinary excretion, not metabolic processes.

Q: A patient named Ram Prasad is admitted to Guru Teg Bahadur Hospital with a respiratory infection. Tobramycin is ordered for treatment. Given that the clearance and volume of distribution of tobramycin in him are 160 mL/min and 40 L, respectively, calculate the intravenous loading dose required to achieve a therapeutic plasma concentration of 4 mg/L.

160 mg. ***160 mg*** - The loading dose is calculated using the formula: **Loading Dose = Volume of Distribution (Vd) × Target Plasma Concentration (Cp)**. - Given Vd = 40 L and Cp = 4 mg/L, the calculation is 40 L × 4 mg/L = **160 mg**. *0.1 mg* - This value is significantly too low for a therapeutic loading dose of tobramycin and would not achieve the desired concentration. - It likely results from incorrect units or a miscalculation of the formula. *10 mg* - This dose is too low to reach the therapeutic plasma concentration of 4 mg/L given the patient's volume of distribution. - It suggests a calculation error, possibly dividing Vd by Cp instead of multiplying. *115.2 mg* - This value indicates a calculation error, as it does not correspond to the correct application of the loading dose formula. - It might arise from using an incorrect volume of distribution or target concentration, or an error in multiplication.

Q: At toxic doses, zero-order kinetics is seen in which of the following substances?

Phenytoin. ***Phenytoin*** - **Phenytoin** exhibits **zero-order kinetics** at toxic (saturating) doses because its metabolic enzymes become saturated, leading to a constant amount of drug eliminated per unit time rather than a constant fraction - This property makes its plasma concentration disproportionately increase with small dose adjustments once the enzymes are saturated, greatly increasing the risk of **toxicity** - Phenytoin is the **classic example** of capacity-limited metabolism due to saturation of hepatic enzymes (CYP2C9 and CYP2C19) *Penicillin* - Penicillin generally follows **first-order kinetics**, meaning a constant fraction of the drug is eliminated per unit time, and its elimination rate is proportional to its concentration - It is not commonly associated with zero-order kinetics even at higher doses, as its elimination pathways (renal excretion and metabolism) are typically not saturated within therapeutic or moderately toxic ranges *Valproate* - Valproate primarily follows **first-order kinetics** within its therapeutic range, with its elimination rate dependent on the drug concentration - While it can exhibit non-linear kinetics at very high concentrations due to protein binding saturation and enzyme saturation, it is less commonly cited as a classic example of zero-order kinetics compared to phenytoin *Carbamazepine* - Carbamazepine follows **first-order kinetics** within its therapeutic window - It undergoes **autoinduction** of its own metabolism, meaning that with continued dosing, its metabolic enzymes become more active, leading to increased elimination over time rather than saturation-induced zero-order kinetics

Q: What does the term 'tolerance' refer to in pharmacology?

Decreased effect of drug on the same dose. ***Decreased effect of drug on the same dose*** - **Tolerance** is a state in which the body's response to a drug is **reduced** over time, requiring higher doses to achieve the same effect. - This phenomenon often develops with **repeated exposure** to a drug, leading to a need for dose escalation. *Increased effect of drug on the same dose* - This describes **sensitization** or **reverse tolerance**, where the body becomes more responsive to the drug over time, which is the opposite of tolerance. - It is not a characteristic feature of pharmacological tolerance. *Same effect at lower doses* - This would imply an **increased sensitivity** to the drug, meaning that less drug is needed to achieve the desired effect. - This is contrary to the definition of tolerance, which requires higher doses for the same effect. *No effect* - While extreme tolerance can lead to a point where a drug has minimal or no clinical effect at standard doses, "no effect" itself is not the primary definition of tolerance. - Tolerance refers to the gradual **reduction in effect**, rather than an immediate absence of effect.

Q: What is the term used to describe the phenomenon where individuals with liver damage experience heightened effects from smaller doses of alcohol?

Reverse tolerance. ***Reverse tolerance*** - This term describes the phenomenon where individuals with **liver damage**, particularly due to chronic alcohol use, become more sensitive to the effects of alcohol. - The damaged liver is less efficient at metabolizing alcohol, leading to higher and longer-lasting blood alcohol concentrations, even with smaller doses. - This represents a **decrease in tolerance** (increased sensitivity), where smaller amounts of alcohol produce heightened effects due to impaired hepatic clearance. *Withdrawal* - **Withdrawal** refers to the set of symptoms that occur when a person who is physically dependent on a substance, like alcohol, stops or significantly reduces their intake. - It is characterized by symptoms such as tremors, seizures, and delirium, and is distinct from the **heightened effects of alcohol** from a small dose. *Mellanby phenomenon* - The **Mellanby phenomenon** describes the observation that the effects of alcohol are more pronounced when blood alcohol levels are rising compared to when they are falling, even if the absolute blood alcohol concentration is the same. - This relates to the acute dynamics of alcohol's effect on the brain, not to chronic liver damage increasing sensitivity to small doses. *Cross tolerance* - **Cross tolerance** occurs when an individual develops tolerance to one drug, and this tolerance extends to another, pharmacologically similar drug, often due to shared metabolic pathways or receptor systems. - It does not describe an increased sensitivity to the original substance due to organ damage, but rather a reduced response to a different substance.

Question 1

Which of the following drugs should be given in a sustained-release oral dosage form?

Accepted Answer

An antihypertensive with a plasma half-life of 3 hours

Answer

An anti-arrhythmic drug with a plasma half life of 10 seconds used for acute treatment of PSVT

Answer

Anti inflammatory drugs with the plasma half life of 24 hours

Answer

Hypnotic drugs with a plasma half life of 2 hours

Question 2

Which of the following statements is true regarding competitive reversible antagonism?

Accepted Answer

Efficacy and Vmax remain unchanged.

Answer

ED50 remains unchanged in competitive reversible antagonism.

Answer

Potency remains unchanged in the presence of a competitive antagonist.

Answer

Affinity (Kd) remains unchanged in competitive reversible antagonism.

Question 3

A partial agonist has:

Accepted Answer

High affinity with low intrinsic activity

Answer

High affinity with no intrinsic activity

Answer

Low affinity with high intrinsic activity

Answer

Low affinity with low intrinsic activity

Question 4

Which of the following is a metabotropic receptor?

Accepted Answer

Beta receptor for norepinephrine

Answer

GABA-A receptor

Answer

NMDA receptor

Answer

Nicotinic acetylcholine receptor

Question 5

Renal threshold of a drug means:

Accepted Answer

Drug concentration above which it appears in urine

Answer

Drug concentration below which it appears in urine

Answer

Drug concentration above which it appears in blood

Answer

Drug concentration at which it starts to be metabolized

Question 6

A patient named Ram Prasad is admitted to Guru Teg Bahadur Hospital with a respiratory infection. Tobramycin is ordered for treatment. Given that the clearance and volume of distribution of tobramycin in him are 160 mL/min and 40 L, respectively, calculate the intravenous loading dose required to achieve a therapeutic plasma concentration of 4 mg/L.

Accepted Answer

160 mg

Answer

0.1 mg

Answer

10 mg

Answer

115.2 mg

Question 7

Which of the following describes the first-pass metabolism?

Accepted Answer

Drug given orally is metabolized by the liver before entering the circulation.

Answer

Drug given intravenously bypasses the liver initially.

Answer

Gastric acids primarily affect the stability of drugs.

Answer

Absorption of a drug occurs in the intestines.

Question 8

At toxic doses, zero-order kinetics is seen in which of the following substances?

Accepted Answer

Phenytoin

Answer

Valproate

Answer

Carbamazepine

Answer

Penicillin

Question 9

What does the term 'tolerance' refer to in pharmacology?

Accepted Answer

Decreased effect of drug on the same dose

Answer

Increased effect of drug on the same dose

Answer

Same effect at lower doses

Answer

No effect

Question 10

What is the term used to describe the phenomenon where individuals with liver damage experience heightened effects from smaller doses of alcohol?

Accepted Answer

Reverse tolerance

Answer

Withdrawal

Answer

Mellanby phenomenon

Answer

Cross tolerance

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?